Three patients didn’t have the treatment . Efficacy The principal outcome at 90 days is shown in Figure 1Figure 1Modified Rankin Score at three months According to Treatment Group. A total of 55 of the 181 individuals in the endovascular-treatment group survived without disability , in comparison with 63 of the 181 patients . The chances ratio modified for the main element variables was 0.71 . At 90 days, 26 individuals in the endovascular-treatment group and 18 in the intravenous t-PA group had died . There were no significant distinctions between the groups with regards to the secondary outcome measures . Safety Complications in the seven days after randomization in the endovascular-treatment group and the intravenous t-PA group included death, neurologic deterioration, nonfatal and fatal symptomatic intracranial hemorrhage, fatal and non-fatal symptomatic edema from an original brain infarction, non-fatal recurrent ischemic stroke, and extracerebral events.All efficacy analyses were predicated on the intention-to-treat principle, comparing groups based on the randomly designated treatment. For the principal efficacy evaluation for noninferiority, we completed a per-protocol evaluation also, which included patients who received process treatments as planned. The cumulative incidence of relapse was approximated by using the proper non-parametric estimator, and between-group comparisons had been performed with Gray’s K-sample test. SAS statistical software, version 9.1.3, was used for all analyses. Results Enrollment and Characteristics of the Patients Enrollment of the prespecified 162 patients was were only available in October 2007 and was completed in September 2010.